Skip to main content
Bone & Joint Research logoLink to Bone & Joint Research
. 2025 Oct 27;14(10):901–914. doi: 10.1302/2046-3758.1410.BJR-2024-0477.R1

Genotype and phenotype correlation analysis in 27 families with multiple osteochondroma and validation by ATDC5 chondrocyte models

Xiaoyan Guo 1,2,✉, Mingrui Lin 3, Shan Xu 4, Boling Liu 5, Rui Zhang 1, Shu Liu 1, Yuancheng Pan 5
PMCID: PMC12558417  PMID: 41144229

Abstract

Aims

This study aimed to explore the genotype and phenotype correlation of patients with multiple osteochondroma (MO), and validate phenotypic differences in ATDC5 cell model with EXT1 or EXT2 gene disruption (EXT1-/- or EXT2-/-).

Methods

Mutation analysis was employed in 27 families with MO using polymerase chain reaction (PCR)-Sanger sequencing and targeted next-generation sequencing (t-NGS). ATDC5 cell model with EXT1-/- or EXT2-/- was established using CRISPR/Cas9 technology. Markers of chondrocyte proliferation and differentiation were assessed through quantitative real-time polymerase chain reaction (qRT-PCR), Western blotting, and dyeing experiments at different timepoints.

Results

A total of 27 pathogenic mutations were identified in EXT1 and EXT2 genes, in which nine were novel mutations. In terms of mutation rate, onset age, medical treatment age, and numbers of moderate/severe (II/III) patients, the numbers with EXT1 gene mutations were more than those with EXT2 gene mutations. ATDC5 cell model with EXT1-/- or EXT2-/- was successfully established. The proliferation rate of ATDC5 chondrocytes in mutant groups (EXT1-/- and EXT2-/-) was higher than in WT group. The expressions of proliferation markers, including α-1 chain of type II collagen (COL2A1), aggrecan (ACAN), and SRY-box transcription factor 9 (SOX9), were almost all higher in mutant groups than that in WT group. Moreover, the expression of differentiation indicators, including α-1 chain of type X collagen (COL10A1), Runt-related transcription factor 2 (RUNX2), and matrix metallopeptidase 13 (MMP13), was increased in mutant groups compared to WT group. The Alcian blue and Alizarin red staining obtained similar results.

Conclusion

Clinical research identified nine novel mutations in EXT1 and EXT2 genes from 27 families with MO, and patients with EXT1 mutations have more severe symptoms than with EXT2 mutations. Cellular experiments suggested that EXT1 and EXT2 gene mutations promote proliferation and differentiation of chondrocytes, which were consistent with clinical research.

Cite this article: Bone Joint Res 2025;14(10):901–914.

Keywords: Multiple osteochondromas, EXT1 and EXT2 genes, CRISPR/Cas9, ATDC5 cell, Multiple osteochondroma, chondrocytes, Western blot, staining, collagen, MMP13, COL2A1, Alcian blue, quantitative real-time polymerase chain reaction, aggrecan

Article focus

  • Genotype and phenotype correlation analysis in multiple osteochondroma (MO) patients with EXT1 or EXT2 gene mutations.

  • Establishment of an ATDC5 cell model with EXT1-/- or EXT2-/-, validation of cell phenotype for future intensive studies.

Key messages

  • Patients with EXT1 mutations tend to have more severe clinical manifestations and higher rate of deterioration than with EXT2 mutations.

  • EXT1 and EXT2 gene mutations promote proliferation and differentiation of chondrocytes.

  • Extracting chondrocytes with homozygous mutations in MO tissues is difficult at present, but constructing ATDC5 cell model with EXT1-/- or EXT2-/- may solve this problem.

Strengths and limitations

  • We identified nine novel mutations in EXT1 and EXT2 genes, and found that patients with EXT1 gene mutations had more severe symptoms than with EXT2 mutations.

  • An ATDC5 cell model with EXT1-/- or EXT2-/- was successfully constructed for the first time. Results of cellular experiments were consistent with clinical research.

Introduction

Multiple osteochondroma (MO) is a skeletal disorder characterized by the formation of multiple bony protuberances, commonly arising from the epiphyseal growth plates of bones during skeletal growth.1 MO is one of the most common skeletal dysplasias in humans and is characterized by an autosomal dominant inheritance pattern. In MO, osteochondromas develop in various types of bones, including flat bones, vertebrae, and ribs; however, they are especially common at the distal ends of long bones. Currently, the main aetiology of MO is mutations in the EXT1 (8q24.1)2 and EXT2 (11p11-p12)3 genes, which introduce an early termination codon and result in partial or total EXT gene deletion and ultimately loss of protein function. Approximately 80% of mutations in EXT1 or EXT2 genes in patients with MO are nonsense, frame-shift, or splicing-site mutations, although large fragment deletions or insertions have been reported in rare instances.4,5

Currently, the pathogenic mechanism of MO remains ambiguous. EXT1 and EXT2 are two tumour suppressor genes and encode two glycosyltransferases that catalyze the elongation and synthesis of heparan sulphate (HS) chains on proteoglycans (PGs).6 Researchers have proposed that copolymerase activity is reserved in the EXT1 protein, and the EXT1 and EXT2 oligomeric complex is a requisite for the proper localization of EXT1 in the Golgi apparatus.6,7 Genotype and phenotype correlation studies suggest that symptoms of patients with MO who have EXT1 mutations tend to be more severe compared to those in patients with EXT2 mutations.8 Currently, haploinsufficiency and loss of heterozygosity (LOH) are two important viewpoints in MO; however, according to the two-hit model for classic tumour suppressor genes and some clinical research and animal experiments, LOH is an important molecular mechanism of MO.9-11 Animal experiments also indicated that mice with heterozygous EXT1 or EXT2 genes, which mimic the human genotypes of MO, occasionally grew solitary osteochondroma-like protuberances on their ribs and hardly had any osteochondroma formation in long bones,12,13 whereas mice with clonal inactivation of the EXT1 gene or chondrocyte-specific somatic mutations in the EXT1 gene developed MOs, and their phenotypes were nearly identical to those of human patients with MO. Therefore, LOH appears to play an important role in the pathogenesis of MO, while homozygous deficiency of EXT1 is a requisite for the development of osteochondroma chondrocytes. Additionally, these osteochondromas were verified to originate from proliferating physeal chondrocytes.9,14

Due to the presence of Cas9 with endonuclease activity, the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 system is currently the simplest and most extensively used gene editing tool in genetic research.15 Compared to previous editing techniques, such as zinc finger nucleases and transcription activation-like effect nucleases,16 CRISPR/Cas9 has higher specificity and efficiency, and has been broadly applied in several hereditary and acquired illnesses, such as cancers, cardiovascular diseases, visual maladies, haemolytic diseases, neurodegenerative conditions, immunodeficiency disorders, and some X-linked disorders.17-22

CRISPR-Cas9 technology has been applied in research on gene function and CRISPR-based disease model construction, including cell and animal models.23-27 Stable chondrocyte cell lines with ablation of aggrecan expression (ACAN KO) have also been effectively generated from Rat Chondrosarcoma Swarm (RCS) Cas9 cells using CRISPR-Cas9 technology, which provides a valuable and powerful tool for gene function studies in chondrocytes.27 Cartilage is a highly specialized connective tissue, in which chondrocytes serve as the sole resident cell type. ACAN, type II collagen (COL2), SRY-box transcription factor 9 (SOX9), Runt-related transcription factor 2 (RUNX2), type X collagen (COL10), and matrix metallopeptidase 13 (MMP13) are chondrogenic proliferation and differentiation-related markers.28-30 Derived from mouse teratoma cells, ATDC5 cells are a chondrogenic cell line and have proved to be an excellent in vitro model for molecular mechanism research involved in chondrogenesis; it is indicated that dual gene knockout of EXT1 and FGFR3 could promote chondrocyte differentiation and lead to osteochondroma formation.29 This study aimed to explore the genetic basis and molecular mechanisms underlying MO and to elucidate the correlation between genotype and phenotype in affected individuals. Additionally, the study sought to develop and evaluate ATDC5 cellular models to investigate the impact of EXT1 and EXT2 gene disruptions on chondrocyte proliferation and differentiation, providing a platform for future research into MO pathogenesis and potential therapeutic strategies.

Methods

Study participants

A total of 27 patients diagnosed with MO from the Department of Orthopedics in Fuzhou Second General Hospital were included in the study (Table I). Written informed consent was obtained from each participant or their guardians prior to inclusion in the study, and the study was approved by Ethics Committee of Fuzhou Second General Hospital. All procedures were in accordance with the principles of the Declaration of Helsinki.31

Table I.

Clinical features of multiple osteochondroma (MO) probands from the Paediatric Orthopedics department in this study.

Patient ID Age,
yrs
Discovery time, yrs* Sex Involved sites Dysfunction and deformities Family history
1 16 6 Male Bilateral upper arms, shoulders and knees, pelvis Left forearm Negative
2 9 9 Male Bilateral distal radius, femur, tibia, and fibula Hip joints Negative
3 11 1 Male Bilateral knee and ankle joints, bilateral forearms, and chest. Hip and ankle joints Positive
4 6 4 Female The distal part of left forearm, right forearm, and right upper arm Left forearm Positive
5 10 3 Female The proximal part of upper arms, the distal part of forearms, proximal interphalangeal left middle finger, and the joints of knees Right wrist and knee joints Positive
6 3 3 Male The joints of ankles None Negative
7 9 3 Male The joints of wrists and knees Knee joints Positive
8 9 8 Male The distal part of right ulna and bilateral femora, the proximal and distal parts of bilateral tibia None Negative
9 5 1 Male The joints of left wrist, the proximal part of left tibia and fibula, and the distal part of right femur None Negative
10 6 5 Male The distal part of bilateral ulna and radius Bilateral forearms Negative
11 12 5 Male The distal part of left ulna and radius None Positive
12 5 4 Male The joint of left wrist (in the side of radius), the proximal part of left tibia and fibula, and the distal part of right femur None Negative
13 7 1 Female The proximal part of bilateral tibia and fibula, and the distal part of bilateral femora None Positive
14 6 4 Male The proximal part of right humerus and around the joint of right wrist (in the side of ulna) None Positive
15 8 2 Male The left forearm, right upper arm, and two knees None Negative
16 5 4 Male The joints of wrists and knees, and the left upper arm Elbow joints Negative
17 8 5 Male Bilateral femora and left tibia and fibula None Positive
18 18 16 Male Bilateral femur, tibia and fibula, upper humerus, inner upper edge of left scapula, right clavicle, and part of right ribs None Positive
19 21 11 Male Right neck of femur, bilateral lower femora, upper tibia and fibula Knee Positive
20 14 14 Male Bilateral lower femora and tibiofibula None Negative
21 58 50 Male Bilateral femur and pelvis None Negative
22 29 29 Male Both knees None Negative
23 30 24 Male Lower right femur, upper tibia and fibula None Negative
24 31 11 Male Right femur, upper tibia and fibula, multiple metatarsals, first proximal toe Knee joints Positive
25 17 1 Male Bilateral distal femur, upper tibia and fibula, upper humerus, left scapula None Positive
26 32 29 Male Lower left femur and upper right tibia None Negative
27 17 7 Male Left distal femur, left proximal fibula Left knee joint Negative
*

Osteochondroma of the patients is discovered by the parents for the first time.

Mutation analysis of EXT1 and EXT2 genes in MO patients using PCR-Sanger sequencing and t-NGS

Genomic DNA was extracted from the peripheral blood of 27 patients with MO using the SE Blood DNA kit (Omega, USA). Coding regions and adjacent intronic sequences (≥ 10 base pairs) of the EXT1 and EXT2 genes were amplified and sequenced using Sanger sequencing or directly using targeted next-generation sequencing (t-NGS) as previously described.32-34 Polymerase chain reaction (PCR) amplification products were purified and then sequenced bidirectionally on an ABI 3730 XL genetic analyzer (Applied Biosystems; Thermo Fisher Scientific, USA), and Chromas (Technelysium, Australia) was used to view and interpret the sequencing results.

Cell culture

HEK 293 T was maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml of penicillin, and 100 mg/ml of streptomycin at 37°C with 5% CO2. ATDC5 cells were maintained in a 1:1 mixture of DMEM and Ham’s F-12 medium (BasalMedia, China), supplemented with 10% FBS, 100 U/ml of penicillin, and 100 mg/ml of streptomycin in a humidified atmosphere of 5% CO2 at 37°C. For ATDC5-induced chondrocytes, a determined number of ATDC5 cells were inoculated into cell flasks containing DMEM/F12 (1:1) with 5% FBS. To induce chondrocyte differentiation, 1% insulin-transferrin-selenium (ITS) (BasalMedia) was added to the medium and cultured for 21 days. The culture medium was replaced daily.

Designing CRISPR/Cas9 plasmids that target EXT1 and EXT2 genes

Four and three pairs of single-guide RNA (sgRNA) targets of murine EXT1 and EXT2 genes, respectively, were designed on the database of E-CRISP,35 and two pairs of verified primers for each gene were designed using Primer-BLAST of NCBI database (Supplementary Table i).36 Lentiviral-V2-green fluorescent protein (GFP) vectors were digested (FastDigest enzyme BbsI; Thermo Fisher Scientific) and purified (MiniBEST DNA Agarose Purification Kit; TaKaRa, Japan), and then mixed with annealed sgRNAs to obtain recombinant vectors (Figure 1a). Additionally, 250 μl of serum-free DMEM medium and 10 μg of lentiviral-V2-GFP recombinant plasmids, helper plasmids pMD2.G, and pSPAX2 (transfected ratio: 4:3:2) were mixed completely with 250 μl of serum-free DMEM medium and 30 μl of transfection reagent PolyJet (SignaGen Laboratories, USA) for 15 minutes. Afterward, the mixture was added into 293 T cells. After 72 hours of transfection, viruses were collected, purified, and preserved in a refrigerator at -80°C. ATDC5 cells were infected with viruses, cell fluorescence expression was observed, and GFP-positive cells were sorted using flow cytometry.

Fig. 1.

Lentiviral vector construction for sgRNA targeting EXT1/EXT2 genes, showing primer design, Esp3I/PshAI insertion sites, vector map with Cas9 and GFP, and sequencing chromatograms confirming sgRNA integration. Construction and verification of the lentiviral vector for single-guide RNA (sgRNA) expression. a) A schematic diagram illustrates the design of oligo primers for sgRNAs targeting the EXT1 and EXT2 genes, highlighting Esp3I restriction sites. The guide oligo insertion site in the original vector is flanked by Esp3I and PshAI regions, which are ligated into a digested vector. The Lenti-V2-GFP vector map includes the U6 promoter, Esp3I sites, SpCas9, a 2A peptide, and a GFP/puromycin resistance cassette. b) Sequencing chromatograms confirm successful insertion of sgRNAs into vectors for four constructs: EXT1-SG1, EXT1-SG3, EXT2-SG1, and EXT2-SG4.

Schematic diagram of Lentiviral-V2-GFP-sg-EXT1 and Lentiviral-V2-GFP-sg-EXT2 recombinant plasmids and sequencing verification. a) Schematic diagram of constructing recombinant plasmids. b) Sequencing verification of recombinant plasmids of Lentiviral-V2-GFP-sg-EXT1 and Lentiviral-V2-GFP-sg-EXT2. GFP, green fluorescent protein.

To verify the efficiency of sgRNA editing, ATDC5 cells were collected and DNA was extracted using a Genomic DNA Extraction Kit (Code No. 9765; TaKaRa), and two editing fragments (part of exon 1 in EXT1 gene and exon 2 in EXT2 gene) were amplified with verified primers of EXT1 and EXT2 genes (Supplementary Table i). Additionally, 5 μl of PCR products were analyzed using T7E1 (Viewsolid Biotech; China) and subsequently sequenced (Sangon Biotech, China). Digestion products were separated on 2% agarose gel. Monoclonal cell line was separated from GFP positive cells. TA clone (pMD19-T Vector Cloning Kit; TaKaRa), PCR-Sanger sequencing, and Western blot were used to verify the efficiency of sgRNA editing for the monoclonal colonies. The procedure of Western blot analysis targeting EXT1 and EXT2 proteins is described below.

Quantitative real-time polymerase chain reaction

According to the manual’s instructions, total RNA from four groups (blank group, WT group, EXT1-/- group, and EXT2-/- group) was extracted using TRIzol (Thermo Fisher Scientific, China) and then reversely transcribed into complementary DNA (cDNA) (Vazyme, China). The quantitative real-time polymerase chain reaction (qRT-PCR) system contained 10 μl of Taq Pro Universal SYBR qPCR Master Mix (Vazyme), 0.5 μl of each primer, 100 ng of cDNA, and double-distilled water (ddH2O) for a total reaction volume of 20 μl. The primers were designed as before, and sequences of four genes are listed in Supplementary Table ii. The amplification condition was a denaturation step at 95°C for 30 seconds, followed by 40 cycles of amplification at 95°C for ten seconds and 60°C for 30 seconds. The procedure was conducted on a PCR Thermal Cycler (ABI QuantStudio 6 Flex; QuantStudio, Thermo Fisher Scientific). The 2-∆∆Ct method was used to calculate the relative gene expression.

Cell proliferation assay

The proliferation rate of ATDC5 chondrocytes from four groups was detected using the Cell Counting Kit-8 (CCK-8) assay (MedChemExpress (MCE), USA). Briefly, 100 μl of cell suspension was added to each well of 96-well plates; the plates were then cultured at 37°C for 24 hours. Furthermore, 10 μl of CCK-8 solution was added to each well and thoroughly mixed; the plate was then incubated at 37°C for another one to four hours. The microplate spectrophotometer (CLARIOstar Plus; BMG LABTECH, Germany) was used to detect the optical density (OD) values at 450 nm.

Western blotting analysis

These methods have been reported in previous studies.37,38 ATDC5 chondrocytes were collected and then resuspended in a lysis buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 0.5 mM ethylene glycol tetraacetic acid (EGTA), and 10% Glycerol, 0.5% NP-40) supplemented with protease and phosphatase inhibitors (Thermo Fisher Scientific). Cell lysates were subjected to centrifugation (14,000 rpm, 10 mins, 4°C), and obtained supernatants were collected for immunoblotting. The concentrations of total protein were determined using the BCA protein assay kit (Beyotime Biotechnology, China). Equal amounts of different protein samples were separated by SDS-PAGE, and then transferred onto polyvinylidene difluoride (PVDF) membranes (Merck, Germany) using a semi-dry transfer system (Bio-Rad, USA). The PVDF membranes were blocked with 5% non-fat milk in Tris Buffered Saline with Tween (TBST) for one hour at 25°C and incubated using the indicated antibodies. Membranes were probed with primary antibodies as follows: EXT1 (1:1,000 dilution, Thermo Fisher Scientific), EXT2 (1:1,000 dilution, Proteintech, USA), Aggrecan Monoclonal Antibody (BC-3) (ACAN) (1:1,000 dilution, Thermo Fisher Scientific), α-1 chain of type I collagen (COL1A1) (1:1,000 dilution, Cell Signaling Technology (CST), USA), SOX9 (1:5,000 dilution, Proteintech), RUNX2 (1:2,000 dilution, Proteintech), α-1 chain of type X collagen (COL10A1) (1:1,000 dilution, Proteintech), MMP13 (1:1,000 dilution, Proteintech), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1:10,000 dilution, Proteintech), and Tubulin (1:5,000 dilution, Proteintech). The membranes were then washed using TBST buffer three times and incubated with Goat anti-Rabbit IgG H&L (IRDye 800 CW; Thermo Fisher Scientific) preabsorbed ab216773 and anti-mouse IgG H&L (IRDye 680 CW; Thermo Fisher Scientific) preabsorbed ab216776 secondary antibodies at 1:10,000 dilution for one hour at 25°C. The protein signals were analyzed using luminescence.

Alcian blue staining

ATDC5 chondrocytes were incubated in a 12-well culture plate using an ITS differentiation medium for three weeks. The cells were washed using PBS, and fixed in methanol (Sinopharm, China) for five minutes. After being washed with ddH2O and dried, the cells were stained with an Alcian Blue solution (Solarbio, China) for 30 minutes. Finally, the cells were washed twice with ddH2O and were under counterstain for one minute. Images were taken using a microscope (Vert.A1; ZEISS, Germany). Area fraction of glycosaminoglycans in four groups was measured using ImageJ version 1.81 software (National Institutes of Health (NIH), USA).

Alizarin red staining

Until day 21, the culture medium of ATDC5 chondrocytes was discarded, and the cells were washed twice with PBS, then fixed with 4% paraformaldehyde (Beyotime Biotechnology, China) for 15 minutes, before being washed three times with deionized H2O (diH2O). Afterwards, diH2O was completely removed, and 1 ml of 2% Alizarin Red S Stain Solution (ScienCell, USA) was slowly added to each well. The plate was incubated for 20 to 30 minutes at 25°C, then the dye was removed and the plate was washed three to five times with diH2O. Lastly, the plates were drained, and 1 ml of diH2O was added to each well and examined under a microscope. The area fraction of calcium deposition in the four groups was measured using ImageJ version 1.81 software (NIH).

Statistical analysis

Statistical analysis was performed using SPSS 22.0 software (IBM, USA) and GraphPad Prism 10 (GraphPad Software, USA). Analysis of variance (ANOVA) and chi-squared test were used to analyze the clinical data. Two-tailed independent-samples t-test was used for comparisons between groups of cellular experiment data. For comparisons of categorical variables between groups (sex, clinical grading, family history, and mutation type of MO patients), Fisher's exact test was employed first. This was applied preferentially over the chi-squared test under the following conditions: 1) when the total sample size was < 40, or 2) when a 2×2 contingency table had an expected count of < 5. This test provides an exact p-value, effectively avoiding bias introduced by small sample sizes or low event frequencies. A p-value < 0.05 was recognized as statistically significant after group comparison.

Results

Clinical data

All patients were diagnosed based on physical, radiological, and histopathological examinations, and pedigree investigation was also completed for each patient (Figure 2). Among 27 patients, the ratio of sex was 8:1 (male/female), and the mean age at hospitalization was 14.89 years (SD 12.21). Furthermore, 12 patients had a positive history of MO, whereas 15 patients were sporadic cases (Table I).

Fig. 2.

Pedigrees of families with inherited mutations, showing affected individuals and associated variants including deletions, insertions, and substitutions across multiple generations. Pedigree analysis of families with identified genetic mutations. a) Pedigrees of nine families (MO3, MO4, MO5, MO7, MO11, MO13, MO14, MO20, MO26) showing inheritance of various mutations, including deletions (e.g., c.185delT, c.940_941delAG), insertions (e.g., c.649_650insCTGG), and substitutions (e.g., c.1037G>C). Affected individuals are indicated by filled symbols. b) Pedigrees of three additional families (MO17, MO19, MO27) with mutations such as c.1063_1067del, c.540G>A, and e561delG, showing inheritance across generations.

Representative pedigrees of multiple osteochondroma (MO) families with mutations in EXT1 and EXT2 genes. a) EXT1 mutations identified in MO families. b) EXT2 mutations identified in MO families. Question marks indicate the members without definite genotype involved EXT1 or EXT2 gene. Arrows indicate the probands from MO families. WT, wild type.

Mutation detection and genetic analysis

Overall, 27 mutations were identified in the patients, of which nine were novel mutations and 18 had been reported previously (Table II). Approximately 88.9% (24/27) were truncating mutations (nonsense and frame-shift mutations); 16 mutations were identified in the EXT1 gene and 11 were in the EXT2 gene, and the mutation ratio of EXT1 and EXT2 was about 1.45. The results of the analysis are shown in Table III.

Table II.

Variants in EXT1 and EXT2 genes detected in multiple osteochondroma probands in orthopaedics.

Patient ID Gene Exon/intron Variant type cDNA change Protein change ACMG
classification
Variant reported
1 EXT1 Exon 3 Nonsense mutation c.1092 G > A Trp364X Pathogenic (PVS1, PP4) Yes
2 EXT1 Exon 10 Nonsense mutation c.1887 T > A Tyr629X Pathogenic (PVS1,PM2,PP4) Yes
3 EXT1 Exon 1 Frameshift mutation c.185 del T Leu62ArgfsX71 Pathogenic (PVS1,PM2,PP1,PP4) No
4 EXT1 Exon 1 Nonsense mutation c.848 T > A Leu283X Pathogenic (PVS1,PM2,PP1,PP4) Yes
5 EXT1 Exon 2 Missense mutation c.1037 G > C Arg346Thr Pathogenic (PM2,PP1,PP3,PP4) Yes
6 EXT1 Exon 1 Nonsense mutation c.279 C > G Tyr93X Pathogenic (PVS1,PM2,PP4) Yes
7 EXT1 Exon 1 Frameshift mutation c.940_941 del AG Arg314ArgfsX5 Pathogenic (PVS1,PM2,PP1,PP4) No
8 EXT1 Exon 1 Nonsense mutation c.212 T > A Leu71X Pathogenic (PVS1,PM2,PP4) No
9 EXT1 Exon 1 Nonsense mutation c.448 C > T Gln150X Pathogenic (PVS1,PM2, PP4) Yes
10 EXT1 Exon 4 Nonsense mutation c.1236 G > A Trp412X Pathogenic (PVS1,PM2,PP4) Yes
11 EXT1 Exon 11 Nonsense mutation c.2132G > A Trp711X Pathogenic (PVS1,PM2,PP1,PP4) Yes
12 EXT1 Exon 2 Frameshift mutation c.968_969 ins TC Ile324IlefsX47 Pathogenic (PVS1,PM2,PP4) No
13 EXT1 Exon 1 Frameshift mutation c.538_539delAG Ser180SerfsX8 Pathogenic (PVS1,PM2,PP1,PP4) Yes
14 EXT1 Exon 1 Frameshift mutation c.649_650insCTGG Ala217AlafsX8 Pathogenic (PVS1,PM2,PP1,PP4) No
15 EXT2 Exon 3 Frameshift mutation c.199 dup C Val66ValfsX3 Pathogenic (PVS1,PM2,PP4) Yes
16 EXT2 Exon 4 Nonsense mutation c.666 C > A Tyr222X Pathogenic (PVS1,PM2,PP1,PP4) Yes
17 EXT2 Exon 6 Frameshift mutation c.1063_1067delGTTCT Ala355X Pathogenic (PVS1,PM2,PP1,PP4) No
18 EXT2 Exon 3 Nonsense mutation c.540 G > A Trp180X Pathogenic (PVS1,PM2,PP1,PP4) Yes
19 EXT1 Exon 2 Missense mutation c.1037 G > C Arg346Thr Pathogenic (PM2,PP1,PP4) Yes
20 EXT2 Exon 1 Nonsense mutation c.67 C > T Lys23X Pathogenic (PVS1,PM2,PP4) Yes
21 EXT2 Exon 3 Nonsense mutation c.544 C > T Lys182X Pathogenic (PVS1,PM2,PP4) Yes
22 EXT2 Exon 4 Missense mutation c.668 G > C Arg223Pro Pathogenic (PM2,PP4) Yes
23 EXT2 Exon 7 Frameshift mutation c.1171 C > T Gln391X Pathogenic (PVS1,PM2,PP4) No
24 EXT1 Exon 1 Frameshift mutation c.553_560del Asn185X Pathogenic (PVS1,PM2,PP1,PP4) No
25 EXT2 Exon 3 Frameshift mutation c.561delG Leu187LeufsX82 Pathogenic (PVS1,PM2,PP1,PP4) Yes
26 EXT2 Exon 4 Nonsense mutation c.544 C > T Arg182X Pathogenic (PVS1,PM2,PP4) Yes
27 EXT2 Exon 6 Nonsense mutation c.1044 T > A Tyr348X Pathogenic (PVS1,PM2,PP4) No

ACMG, American College of Medical Genetics and Genomics; cDNA, complementary DNA.

Table III.

Genotype and phenotype correlations between EXT1 and EXT2 genes in multiple osteochondroma patients.

Variable EXT1
(n = 16)
EXT2
(n = 11)
p-value
Sex, n
Male 13 11
Female 3 0 0.191*
Mean onset age, yrs (SD) 4.9 (3.3) 16.5 (15.3) 0.007†
Mean age, yrs (SD) 10.4 (7.1) 21.5 (15.2) 0.017†
Clinical grading, n
I 2 8
II to III 14 3 0.002*
Family history, n
Yes 9 3
No 7 8 0.137*
Mutation type, n
Truncating 14 10
Missense 2 1 0.643*
*

Fisher's exact test.

†

Analysis of variance.

Verification of the establishment of ATDC5 cell lines with MO

Two recombinant vectors (Lentiviral-V2-sg-EXT1-GFP, Lentiviral-V2-sg-EXT2-GFP) were selected and verified using bacterial liquid PCR (Figure 1b). Immunofluorescence revealed that the ATDC5 cell lines were effectively transfected (Supplementary Figure a). GFP-positive cells of the blank group, EXT1-sg group (sg-1, sg-3), and EXT2-sg group (sg-1, sg-2) were successfully sorted using flow cytometry (Figure 3). T7E1 digestion results indicated that both EXT1-sg and EXT2-sg groups were cut into two bands, whereas the blank group remained unchanged, therefore both EXT1 and EXT2 genes in ATDC5 cells were edited efficiently using CRISPR-Cas9 (Figure 4). The products of PCR amplification were separated on agarose gel (Figure 4). TA clone and sequencing results indicated that shift mutations were introduced successfully in both mutant groups (Supplementary Table iii). Western blot analysis showed that both EXT1 and EXT2 proteins were entirely knocked out in the two mutant ATDC5 cell lines, compared with the WT ATDC5 cell line, which indicated the editing efficiency of CRISPR-Cas9 at the protein level (Figure 4).

Fig. 3.

Flow cytometry plots showing GFP-positive cell percentages in EXT1 and EXT2 sgRNA groups versus blank controls, with increasing GFP expression indicating successful transduction. Flow cytometry analysis of GFP-positive cells following sgRNA transduction. a) Comparison of EXT1-targeting sgRNAs shows increasing GFP expression: 0.11% in blank control, 5.04% in EXT1-sg1, and 14.14% in EXT1-sg3. b) EXT2-targeting sgRNAs show higher GFP expression: 0.11% in blank, 12.31% in EXT2-sg1, and 24.94% in EXT2-sg2.Each scatter plot displays FSC-A vs FITC-H, with blue dots indicating GFP-positive cells gated in region R3.

Green fluorescent protein (GFP)-positive cells sorted by flow cytometry.

Fig. 4.

PCR and Western blot analyses of EXT1 and EXT2 in ATDC5 cells. Panels show gel bands for sgRNAs and protein expression in wild type and clones, with GAPDH as loading control. Validation of EXT1 and EXT2 gene editing in ATDC5 monoclonal cells. a, b) PCR gel electrophoresis showing successful amplification of EXT1 (sg1, sg3) and EXT2 (sg1, sg2) products, with DNA ladders indicating expected band sizes. c) Western blot analysis of EXT1 protein expression across wild type and multiple clones, with GAPDH as a loading control. d) Western blot analysis of EXT2 protein expression in wild type, clones, and knockdown (KD) samples, also using GAPDH as a control. Protein bands are visible near 70 kD and 30 kD.

Validation of the efficiency of single-guide RNA (sgRNA) editing by enzyme digestion and Western blot. a) Gene editing fragments before enzyme digestion. b) Gene editing fragments after enzyme digestion. c) Monoclonal cells with Lentiviral-V2-GFP-sg-EXT1. d) Monoclonal cells with Lentiviral-V2-GFP-sg-EXT2. These included wild type (WT) and mutant types with Lentiviral-V2-GFP-sg EXT1/EXT2 plasmids infected. In part c), 1-1 and 1-5 indicate the failure of gene editing. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GFP, green fluorescent protein; KD, knockdown; WT, wild type.

EXT1-/- and EXT2-/- models significantly promoted chondrocyte proliferation

The proliferation rate of ATDC5 chondrocytes from four groups at different timepoints was detected using CCK-8 assay. Both ATDC5 chondrocytes in EXT1-/- and EXT2-/- groups manifested a significantly higher proliferation rate at days 6, 12, and 21 compared to chondrocytes in the WT group (Figure 5e).

Fig. 5.

Gene and protein expression analysis in ATDC5 cells with EXT1/EXT2 knockouts, showing RNA levels, Western blots, OD measurements, and glycosaminoglycan staining across time points. Molecular and biochemical characterization of ATDC5 cells under EXT1 and EXT2 knockout conditions. a–c) Bar graphs showing RNA fold changes of ACAN, COL2A1, and SOX9 over 3, 7, 14, and 21 days in Blank, WT, EXT1-/-, and EXT2-/- cells. d) Western blot analysis of protein expression for ACAN, COL2A1, EXT1, EXT2, SOX9, and GAPDH at days 3 and 21. e) Line graph of OD(450 nm) readings over 21 days. f) Microscopic images of glycosaminoglycan staining at day 21 (10× magnification). g) Bar graph quantifying stained area fraction.

The evaluation of cell proliferation of chondrocytes. The expression of proliferation markers of chondrocytes (aggrecan (ACAN), α-1 chain of type II collagen (COL2A1), and SRY-box transcription factor 9 (SOX9)), as measured by a) to c) quantitative real-time polymerase chain reaction (qRT-PCR)) and d) western blot, was significantly higher in EXT1-/- and EXT2-/- groups than in the wild type (WT) group. e) The proliferation rate of the chondrocytes in EXT1-/- and EXT2-/- groups was significantly higher than that in the WT group on days 6, 12, and 21. f) and g) The results of Alcian blue staining (magnification: 10×) on day 21 also showed a significant increase of cartilage glycosaminoglycans (stained blue) in EXT1-/- and EXT2-/- groups compared with the WT group. *p < 0.05, **p < 0.01; independent-samples t-test. Scale bar = 200 μm. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; mRNA, messenger RNA; ns, no significance; OD, optical density.

Results of qRT-PCR suggest that the relative mRNA expression of chondrocyte proliferation-related genes, including ACAN, α-1 chain of type II collagen (COL2A1), and SOX9, in EXT1-/- and EXT2-/- groups was significantly higher than the level in the WT group at days 14 and 21 (Figures 5a to 5c). Western blot analysis obtained similar results indicating that the levels of three proteins were significantly higher than the levels in the WT group at days 3 and 21 (Figure 5d). However, the levels of mRNA expression of COL2A1 in both the EXT1-/- and EXT2-/- groups were relatively higher than the level in the WT group (p > 0.05, independent-samples t-test) at day 14 (Figure 5b).

Observation results of Alcian blue staining showed that at day 21, cartilage glycosaminoglycans were visibly more abundant in the EXT1-/- and EXT2-/- groups than in the WT group (Figures 5f and 5g).

EXT1-/- and EXT2-/- models significantly promoted chondrocyte differentiation

The qRT-PCR results revealed that the relative mRNA expression of chondrocyte differentiation-related genes RUNX2, COL10A1, and MMP13 in the EXT1-/- and EXT2-/- groups was significantly increased compared with the level in the WT group at days 14 and 21 (Figures 6a to 6c), and the relative mRNA expression of RUNX2 and MMP13 in the EXT2-/- group was significantly higher than the level in the EXT1-/- group at day 21 (p < 0.05, independent-samples t-test; Figures 6a and 6c). Western blot analysis also showed similar results, revealing that the levels of three proteins were significantly higher than the levels in the WT group at days 3 and 21 (Figure 6d). Furthermore, Alizarin red staining suggested that at day 21, there was more calcium deposition in the EXT1-/- and EXT2-/- groups than in the WT group (Figures 6e and 6f).

Fig. 6.

ATDC5 cells under EXT1/EXT2 knockout show altered RNA and protein levels of RUNX2, COL10A1, and MMP13, with calcium deposition visualized and quantified at day 21 via staining and area fraction analysis. Analysis of hypertrophic and mineralization markers in ATDC5 cells under EXT1 and EXT2 knockout conditions.(a–c) Bar graphs showing RNA fold changes of RUNX2, COL10A1, and MMP13 over 3, 7, 14, and 21 days in Blank, WT, EXT1-/-, and EXT2-/- cells.(d) Western blot analysis of EXT1, EXT2, MMP13, COL10A1, RUNX2, and GAPDH at days 3 and 21.(e) Alizarin Red S staining images showing calcium deposition at day 21.(f) Bar graph quantifying calcium deposition area fraction.

The evaluation of chondrocyte differentiation. The expression of differentiation markers of chondrocytes (α-1 chain of type X collagen (COL10A1), matrix metallopeptidase 13 (MMP13), and Runt-related transcription factor 2 (RUNX2)), as measured by a) to c) quantitative real-time polymerase chain reaction (qRT-PCR) and d) western blot, was significantly higher in the EXT1-/- and EXT2-/- groups compared with the wild type (WT) group. e) and f) The results of Alizarin red staining (magnification: 10×) on day 21 also showed that calcium deposition (stained red) was significantly increased in the EXT1-/- and EXT2-/- groups compared with the WT group. *p < 0.05, **p < 0.01; independent-samples t-test. Scale bar = 200 μm. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; KD, knockdown; mRNA, messenger RNA; ns, no significance.

Discussion

MO is a childhood-onset and hereditary skeletal deformity with an incidence rate of 1/50,000 at birth, most cases are familial, and 20% to 30% of cases are caused by de novo mutations in the EXT1 and EXT2 genes.39,40 In this study, we detected heterozygous germline mutations in the EXT1 or EXT2 gene of 27 patients or families with MO, and found that the rate of de novo mutations was about 33.33% (9/27) and the male-to-female ratio was 8:1 (24/3), which was higher than those in previous reports.5,41 Furthermore, in our study, we observed a higher incidence of EXT1 mutations (59.26%, 16/27) than EXT2 mutations (40.74%, 11/27), which is consistent with previous reports in Chinese populations.42,43 However, some studies have reported that the incidence of EXT2 mutations is higher than EXT1.44,45 This inconsistency may be due to variations in the recruited number of cases and differences in the ethnic background of the study populations.

Phenotype-genotype studies of MO suggested that patients with EXT1 gene mutations tend to have more severe manifestations than those with EXT2 gene mutations.46-48 In this study, we found that 14 patients (14/27, 51.85%) with EXT1 mutations had dysfunction or deformities that involved joints or long bones, whereas only three patients (3/27, 11.11%) with EXT2 mutations had dysfunctions or deformities (Table III; p < 0.05, Fisher’s exact test). Furthermore, 16 gene mutations were distributed throughout the coding regions of the EXT1 gene; more than 56.25% (9/16) of these mutations were concentrated in exon 1 (Table II), indicating that exon 1 of the EXT1 gene is probably a mutational hotspot in MO. Furthermore, truncated mutations, including nonsense and frame-shift mutations, occurred in approximately 88.89% (24/27) of patients with MO (Table II and Table III).

Previous studies have indicated that chondrocytes from osteochondromas in patients with MO are a mixture of mutant and wild-type cells, with wild-type cells being the major and most abundant chondrocytes in most examined osteochondromas, and the presence of a fraction of chondrocytes with inactivation of EXT1 is sufficient to provoke MOs and thus results in bone deformities, however, the unregulated proliferation of mutant chondrocytes cannot directly cause the subsequent growth of osteochondromas; therefore, it is inferred that mutant cells exert some form of nonautonomous effect on normal cells.9,10 To clarify this, and considering the difficulty in capturing mutant chondrocytes for intensive study, EXT1-/- and EXT2-/- models were constructed using ATDC5 cell lines, which are widely used cell lines in research on chondrocyte development. Proliferation experiments indicated that the proliferation markers (CCK-8, ACAN, COL2A1, and SOX9) in the EXT1-/- and EXT2-/- groups were significantly increased compared with those in the WT group at both the RNA (Days 14 and 21) and protein levels (Day 21) (Figure 5, except for COL2A1 at Day 14), and differentiation experiments also indicated that the differentiation markers (RUNX2, COL10A1, and MMP13) in the EXT1-/- and EXT2-/- groups were significantly increased compared with those in the WT group both in the RNA (Days 14 and 21) and protein levels (Day 21) (Figure 6). Alcian blue and Alizarin red staining also suggested that EXT1-/- and EXT2-/- models significantly promoted the proliferation and differentiation of chondrocytes. These findings indicate that chondrocytes with EXT1 or EXT2 gene deficiency show a greater capability to proliferate and differentiate.

Although clinical studies have shown that patients with EXT1 mutations have more severe symptoms than those with EXT2 mutations, our findings indicate that in ATDC5 cell models, there is no significant difference in the capacity of proliferation between EXT1-/- and EXT2-/- models (Figure 5; p > 0.05). However, we observed a significant difference in the capacity of differentiation between EXT1-/- and EXT2-/- models (RUNX2 and MMP13, Day 21) (Figure 6; p < 0.05), which was consistent with clinical observation that patients with EXT1 mutations have more serious symptoms and tend to deteriorate into osteosarcoma or chondrosarcoma.41,49 The findings in ATDC5 cell models did not completely align with those of the clinical study and previous research. This may be because MO is a skeletal dysplasia rather than a true tumour, and the cell model with absolute ablation of EXT1 or EXT2 gene may be different from animal models of MO.9

In conclusion, our study identified nine novel mutations from 27 cases with MO, and found that patients with EXT1 mutations have more severe symptoms than those with EXT2 mutations. Cellular experiments further confirmed the clinical observations that EXT1 and EXT2 gene mutations promote chondrocyte proliferation and differentiation. Notably, the differentiation capacity in the EXT2-/- group was significantly higher than that in the EXT1-/- group, which indicated that the EXT1 gene plays a leading role in the pathogenesis of MO. Consequently, ATDC5 cell models were successfully constructed and will serve as useful tools for future intensive studies on MO

Author contributions

X. Guo: Formal analysis, Investigation, Methodology, Project administration, Supervision, Writing – original draft

M. Lin: Data curation, Formal analysis, Investigation, Methodology, Writing – review & editing

S. Xu: Data curation, Formal analysis, Methodology, Writing – review & editing

B. Liu: Formal analysis, Investigation, Methodology

R. Zhang: Formal analysis, Investigation, Methodology

S. Liu: Formal analysis, Investigation, Methodology

Y. Pan: Formal analysis, Investigation, Methodology

Funding statement

The authors disclose receipt of the following financial or material support for the research, authorship, and/or publication of this article: this work was supported by Science and Technology Bureau Project of Fuzhou (grant number: 2022-S-017) and the Natural Science Foundation of Fujian Province (grant number: 2024J011272).

ICMJE COI statement

The authors report that this study was funded by Science and Technology Bureau Project of Fuzhou (grant number: 2022-S-017) and the Natural Science Foundation of Fujian Province (grant number: 2024J011272).

Data sharing

All data generated or analyzed during this study are included in the published article and/or in the supplementary material.

Acknowledgements

The authors sincerely acknowledge the Charlesworth Author Services for the English language editing services for the text.

Ethical review statement

This study was approved by the Ethics Committee of Fuzhou Second General Hospital (Approval No.201806010).

Open access funding

The authors report that they received open access funding for their manuscript from the Natural Science Foundation of Fujian Province (grant number: 2024J011272).

Supplementary material

Figure showing detection of ATDC5 cell lines with virus transfection by immunofluorescence. Tables showing sequences of single-guide RNA (sgRNA) targets and verified primers for murine EXT1 and EXT2 genes, sequences of primers used in quantitative real-time polymerase chain reaction, and sequencing results around the target sites of EXT1-SG1 and EXT2-SG1 for the clones. Also included are the full western blots for Figure 4.

© 2025 Guo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND 4.0) licence, which permits the copying and redistribution of the work only, and provided the original author and source are credited. See https://creativecommons.org/licenses/by-nc-nd/4.0/

Data Availability

All data generated or analyzed during this study are included in the published article and/or in the supplementary material.

References

  • 1. Wicklund CL, Pauli RM, Johnston D, Hecht JT. Natural history study of hereditary multiple exostoses. Am J Med Genet. 1995;55(1):43–46. doi: 10.1002/ajmg.1320550113. [DOI] [PubMed] [Google Scholar]
  • 2. Ahn J, Lüdecke HJ, Lindow S, et al. Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1) Nat Genet. 1995;11(2):137–143. doi: 10.1038/ng1095-137. [DOI] [PubMed] [Google Scholar]
  • 3. Ligon AH, Potocki L, Shaffer LG, Stickens D, Evans GA. Gene for multiple exostoses (EXT2) maps to 11(p11.2p12) and is deleted in patients with a contiguous gene syndrome. Am J Med Genet. 1998;75(5):538–540. doi: 10.1002/(sici)1096-8628(19980217)75:5<538::aid-ajmg17>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  • 4. Pedrini E, De Luca A, Valente EM, et al. Novel EXT1 and EXT2 mutations identified by DHPLC in Italian patients with multiple osteochondromas. Hum Mutat. 2005;26(3):280. doi: 10.1002/humu.9359. [DOI] [PubMed] [Google Scholar]
  • 5. Sarrión P, Sangorrin A, Urreizti R, et al. Mutations in the EXT1 and EXT2 genes in Spanish patients with multiple osteochondromas. Sci Rep. 2013;3:1346. doi: 10.1038/srep01346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Senay C, Lind T, Muguruma K, et al. The EXT1/EXT2 tumor suppressors: catalytic activities and role in heparan sulfate biosynthesis. EMBO Rep. 2000;1(3):282–286. doi: 10.1093/embo-reports/kvd045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. McCormick C, Duncan G, Goutsos KT, Tufaro F. The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate. Proc Natl Acad Sci U S A. 2000;97(2):668–673. doi: 10.1073/pnas.97.2.668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Liang Y, Zhang P, Pan W, Tu Y. Insights into pathogenesis, clinical complications and potential treatments of multiple osteochondromas in children: a case report. Asian J Surg. 2024;47(2):1289–1290. doi: 10.1016/j.asjsur.2023.11.071. [DOI] [PubMed] [Google Scholar]
  • 9. Matsumoto K, Irie F, Mackem S, Yamaguchi Y. A mouse model of chondrocyte-specific somatic mutation reveals a role for Ext1 loss of heterozygosity in multiple hereditary exostoses. Proc Natl Acad Sci USA. 2010;107(24):10932–10937. doi: 10.1073/pnas.0914642107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Reijnders CMA, Waaijer CJF, Hamilton A, et al. No haploinsufficiency but loss of heterozygosity for EXT in multiple osteochondromas. Am J Pathol. 2010;177(4):1946–1957. doi: 10.2353/ajpath.2010.100296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Ajmal M, Muhammad H, Nasir M, Shoaib M, Malik SA, Ullah I. Haploinsufficiency of EXT1 and heparan sulphate deficiency associated with hereditary multiple exostoses in a Pakistani family. Medicina (Kaunas) 2022;59(1):100. doi: 10.3390/medicina59010100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Lin X, Wei G, Shi Z, et al. Disruption of gastrulation and heparan sulfate biosynthesis in EXT1-deficient mice. Dev Biol. 2000;224(2):299–311. doi: 10.1006/dbio.2000.9798. [DOI] [PubMed] [Google Scholar]
  • 13. Stickens D, Zak BM, Rougier N, Esko JD, Werb Z. Mice deficient in Ext2 lack heparan sulfate and develop exostoses. Development. 2005;132(22):5055–5068. doi: 10.1242/dev.02088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Jones KB, Piombo V, Searby C, et al. A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes. Proc Natl Acad Sci U S A. 2010;107(5):2054–2059. doi: 10.1073/pnas.0910875107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816–821. doi: 10.1126/science.1225829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Zhang HX, Zhang Y, Yin H. Genome editing with mRNA encoding ZFN, TALEN, and Cas9. Mol Ther. 2019;27(4):735–746. doi: 10.1016/j.ymthe.2019.01.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Zhang M, Eshraghian EA, Jammal OA, Zhang Z, Zhu X. CRISPR technology: the engine that drives cancer therapy. Biomed Pharmacother. 2021;133:111007. doi: 10.1016/j.biopha.2020.111007. [DOI] [PubMed] [Google Scholar]
  • 18. Xing H, Meng LH. CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment. Acta Pharmacol Sin. 2020;41(5):583–587. doi: 10.1038/s41401-019-0322-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Khoshandam M, Soltaninejad H, Mousazadeh M, Hamidieh AA, Hosseinkhani S. Clinical applications of the CRISPR/Cas9 genome-editing system: delivery options and challenges in precision medicine. Genes Dis. 2024;11(1):268–282. doi: 10.1016/j.gendis.2023.02.027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Richards DY, Winn SR, Dudley S, et al. AAV-mediated CRISPR/Cas9 gene editing in murine phenylketonuria. Mol Ther Methods Clin Dev. 2020;17:234–245. doi: 10.1016/j.omtm.2019.12.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Moretti A, Fonteyne L, Giesert F, et al. Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy. Nat Med. 2020;26(2):207–214. doi: 10.1038/s41591-019-0738-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Xu L, Wang J, Liu Y, et al. CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. N Engl J Med. 2019;381(13):1240–1247. doi: 10.1056/NEJMoa1817426. [DOI] [PubMed] [Google Scholar]
  • 23. Maeder ML, Stefanidakis M, Wilson CJ, et al. Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med. 2019;25(2):229–233. doi: 10.1038/s41591-018-0327-9. [DOI] [PubMed] [Google Scholar]
  • 24. Jo DH, Song DW, Cho CS, et al. CRISPR-Cas9-mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis. Sci Adv. 2019;5(10):eaax1210. doi: 10.1126/sciadv.aax1210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Lu Y, Xue J, Deng T, et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat Med. 2020;26(5):732–740. doi: 10.1038/s41591-020-0840-5. [DOI] [PubMed] [Google Scholar]
  • 26. Meisel R. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384(23):e91. doi: 10.1056/NEJMc2103481. [DOI] [PubMed] [Google Scholar]
  • 27. Yang M, Zhang L, Stevens J, Gibson G. CRISPR/Cas9 mediated generation of stable chondrocyte cell lines with targeted gene knockouts; analysis of an aggrecan knockout cell line. Bone. 2014;69:118–125. doi: 10.1016/j.bone.2014.09.005. [DOI] [PubMed] [Google Scholar]
  • 28. Guo L, Guo H, Zhang Y, et al. Upregulated ribosome pathway plays a key role in HDAC4, improving the survival rate and biofunction of chondrocytes. Bone Joint Res. 2023;12(7):433–446. doi: 10.1302/2046-3758.127.BJR-2022-0279.R2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Zhang H, Tang Z, Shen S, et al. Deficiency of EXT1 and FGFR3 genes promotes chondrocyte differentiation, leading to the induction of osteochondroma formation. Bone. 2025;192:117370. doi: 10.1016/j.bone.2024.117370. [DOI] [PubMed] [Google Scholar]
  • 30. Xu J, Ruan Z, Guo Z, et al. Inhibition of SAT1 alleviates chondrocyte inflammation and ferroptosis by repressing ALOX15 expression and activating the Nrf2 pathway. Bone Joint Res. 2024;13(3):110–123. doi: 10.1302/2046-3758.133.BJR-2023-0250.R1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi: 10.1001/jama.2013.281053. [DOI] [PubMed] [Google Scholar]
  • 32. Tian C, Yan R, Wen S, et al. A splice mutation and mRNA decay of EXT2 provoke hereditary multiple exostoses. PLoS One. 2014;9(4):e94848. doi: 10.1371/journal.pone.0094848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Wuyts W, Radersma R, Storm K, Vits L. An optimized DHPLC protocol for molecular testing of the EXT1 and EXT2 genes in hereditary multiple osteochondromas. Clin Genet. 2005;68(6):542–547. doi: 10.1111/j.1399-0004.2005.00538.x. [DOI] [PubMed] [Google Scholar]
  • 34. Guo X, Lin M, Shi T, Yan W, Chen W. Targeted next-generation sequencing newly identifies mutations in Exostosin-1 and Exostosin-2 genes of patients with multiple osteochondromas. Tohoku J Exp Med. 2017;242(3):173–181. doi: 10.1620/tjem.242.173. [DOI] [PubMed] [Google Scholar]
  • 35.No authors listed E-CRISP Design. German Cancer Research Center (DKFZ) [10 October 2025]. http://www.e-crisp.org/index.html date last. accessed.
  • 36.No authors listed Primer designing tool (Primer-BLAST) National Library of Medicine - National Institutes of Health. [10 October 2025]. https://www.ncbi.nlm.nih.gov/tools/primer-blast/ date last. accessed.
  • 37. Li Y, Lin X, Zhu M, et al. A mutation in SLC20A2 (c.C1849T) promotes proliferation while inhibiting hypertrophic differentiation in ATDC5 chondrocytes. Bone Joint Res. 2020;9(11):751–760. doi: 10.1302/2046-3758.911.BJR-2020-0112.R1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Du H, Xiao N, Zhang S, et al. Suppression of TREX1 deficiency-induced cellular senescence and interferonopathies by inhibition of DNA damage response. iScience. 2023;26(7):107090. doi: 10.1016/j.isci.2023.107090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Stieber JR, Dormans JP. Manifestations of hereditary multiple exostoses. J Am Acad Orthop Surg. 2005;13(2):110–120. doi: 10.5435/00124635-200503000-00004. [DOI] [PubMed] [Google Scholar]
  • 40. Porter DE, Emerton ME, Villanueva-Lopez F, Simpson AH. Clinical and radiographic analysis of osteochondromas and growth disturbance in hereditary multiple exostoses. J Pediatr Orthop. 2000;20(2):246–250. [PubMed] [Google Scholar]
  • 41. Caino S, Cubilla MA, Alba R, et al. Clinical and genetic analysis of multiple osteochondromas in a cohort of Argentine patients. Genes (Basel) 2022;13(11):2063. doi: 10.3390/genes13112063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Wang Y, Zhong L, Xu Y, et al. EXT1 and EXT2 variants in 22 Chinese families with multiple osteochondromas: seven new variants and potentiation of preimplantation genetic testing and prenatal diagnosis. Front Genet. 2020;11:607838. doi: 10.3389/fgene.2020.607838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Li Y, Wang J, Tang J, et al. Heterogeneous spectrum of EXT gene mutations in Chinese patients with hereditary multiple osteochondromas. Medicine (Abingdon) 2018;97(42):e12855. doi: 10.1097/MD.0000000000012855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Xu L, Xia J, Jiang H, et al. Mutation analysis of hereditary multiple exostoses in the Chinese. Hum Genet. 1999;105(1–2):45–50. doi: 10.1007/s004399900058. [DOI] [PubMed] [Google Scholar]
  • 45. Al-Zayed Z, Al-Rijjal RA, Al-Ghofaili L, et al. Mutation spectrum of EXT1 and EXT2 in the Saudi patients with hereditary multiple exostoses. Orphanet J Rare Dis. 2021;16(1):100. doi: 10.1186/s13023-021-01738-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Alvarez C, Tredwell S, De Vera M, Hayden M. The genotype-phenotype correlation of hereditary multiple exostoses. Clin Genet. 2006;70(2):122–130. doi: 10.1111/j.1399-0004.2006.00653.x. [DOI] [PubMed] [Google Scholar]
  • 47. Porter DE, Lonie L, Fraser M, et al. Severity of disease and risk of malignant change in hereditary multiple exostoses. A genotype-phenotype study. J Bone Joint Surg Br. 2004;86-B(7):1041–1046. doi: 10.1302/0301-620x.86b7.14815. [DOI] [PubMed] [Google Scholar]
  • 48. Pedrini E, Jennes I, Tremosini M, et al. Genotype-phenotype correlation study in 529 patients with multiple hereditary exostoses: identification of “protective” and “risk” factors. J Bone Joint Surg Am. 2011;93-A(24):2294–2302. doi: 10.2106/JBJS.J.00949. [DOI] [PubMed] [Google Scholar]
  • 49. Cao L, Liu F, Kong M, et al. Novel EXT1 mutation identified in a pedigree with hereditary multiple exostoses. Oncol Rep. 2014;31(2):713–718. doi: 10.3892/or.2013.2891. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

All data generated or analyzed during this study are included in the published article and/or in the supplementary material.


Articles from Bone & Joint Research are provided here courtesy of British Editorial Society of Bone and Joint Surgery

RESOURCES